Table 1.
Clinical trials investigating the association of RAS inhibitors with health outcomes in COVID-19 patients. RAS, renin-angiotensin system; ACEi, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; DRI, direct renin inhibitor
| Identifier | Status | Model | Aim | Population size |
|---|---|---|---|---|
| NCT04318418 | Not yet recruiting |
Observational Case-control |
Association of ACEi or ARBs to severe COVID-19 | 5000 |
| NCT04364893 | Recruiting | Interventional | Suspension of ACEi or ARB on the length of hospital stay and mortality | 500 |
| NCT04374695 | Not yet recruiting |
Observational Case-control |
Relationship of ACEi and ARBs with COVID-19 infection and severity | 700 |
| NCT04357535 | Terminated | Observational | Association of ACEi or ARBs with prognosis of patients with COVID-19 | 17 |
| NCT04331574 | Recruiting | Observational | Effects of chronic intake of RAS inhibitors on the prevalence and severity of the clinical manifestation of COVID-19 | 2000 |
| NCT04338009 | Enrolling by invitation | Interventional | Clinical impact of continuation vs. discontinuation of ACEi and ARBs on outcomes in patients hospitalized with COVID-19 | 152 |
| NCT04330300 | Recruiting | Interventional | Switch to an alternative blood pressure medication or continue with the ACEi/ARB in hypertensive patients | 2414 |
| NCT04345406 | Not yet recruiting | Interventional | Investigation of ACEi in treatment of COVID-19 | 60 |
| NCT04353596 | Recruiting |
Interventional Case-control |
The association of stopping chronic ACEi/ARB therapy in SARS-CoV-2-infected patients with outcomes | 208 |
| NCT04374110 | Recruiting | Observational | Monitoring of drug safety and the occurrence of complications during hospitalization in patients with cardiovascular diseases with COVID-19 | 1000 |
| NCT04371289 | Not yet recruiting | Observational | Investigation of cardiovascular risk in COVID-19 patients during acute disease and at short-term follow-up | 5500 |
| NCT04351581 | Recruiting | Interventional | Investigate whether to continue or discontinue treatment with ACEi or ARBs in hospitalized patients with COVID-19 | 215 |
| NCT04345406 | Not yet recruiting | Interventional | The effect of ACEi in the treatment of COVID-19 | 60 |
| NCT04329195 | Recruiting | Interventional | Determining whether RAS blockers should be discontinued or not in patients with COVID-19 | 554 |
| NCT04338009 | Enrolling by invitation | Interventional | Assessing the clinical impact of continuation vs. discontinuation of ACEi and ARBs on the outcomes in patients hospitalized with COVID-19 | 152 |
| NCT04367883 | Recruiting | Observational | Evaluation of influenza vaccination and treatment with ACEi and RAIII in the evolution of SARS-COVID-19 infection | 2574 |
| NCT04364984 | Recruiting | Observational | Monitoring hypertensive patients receiving ARBs or DRI or ACEi with COVID-19 infection | 10 |
| NCT04353596 | Recruiting | Interventional | Stopping ACEi in patients with COVID-19 to improve outcomes | 208 |
| NCT04318418 | Not yet recruiting |
Observational Case-control |
The effect of treating COVID-19 patients with ARB or ACEi compared with treatment without these medications | 5000 |
| NCT04356417 | Not yet recruiting | Observational | The effect of synthetic antimalarial and anti-hypertensive drugs on preventing serious COVID-19 infections | 6,000,000 |
| NCT04394117 | Not yet recruiting | Interventional | Effectiveness of ARBs on improving the outcomes of COVID-19 patients | 605 |
| NCT04340557 | Recruiting | Interventional | Investigation of ARBs on progression to acute respiratory distress syndrome with SARS-CoV-2 infection | 100 |
| NCT04337190 | Recruiting | Observational | Determining ACE2 level and activity in patients with SARS-CoV-2 infection admitted to ICU | 100 |
| NCT04335786 | Recruiting | Interventional | Investigation of valsartan for prevention of acute respiratory distress syndrome in hospitalized patients with COVID-19 | 651 |
| NCT04337008 | Recruiting | Interventional | Effectiveness of RAS blocker treatments in patients with COVID-19 | 50 |
| NCT04287686 | Withdrawn | Interventional | Recombinant human angiotensin-converting enzyme 2 as a treatment for patients with COVID-19 | 0 |